YMAB Dividend: Y-mAbs Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

YMAB Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	85	87	84	65	34	20
Revenue Growth (YoY)	-1%	4%	28.99%	91%	70%	--
Cost of Revenue	15	15	11	7	2	--
Gross Profit	69	72	73	57	32	--
Selling, General & Admin	49	54	43	60	54	44
Research & Development	44	48	50	91	93	93
Operating Expenses	96	102	94	152	148	140
Other Non Operating Income (Expenses)	4	0	3	0	-3	1
Pretax Income	-22	-29	-20	-95	-55	-119
Income Tax Expense	0	0	0	--	--	--
Net Income	-22	-29	-21	-95	-55	-119
Net Income Growth	-8%	38%	-78%	73%	-54%	47%
Shares Outstanding (Diluted)	45.31	44.32	43.64	43.7	43.18	40.12
Shares Change (YoY)	3%	2%	0%	1%	8%	14%
EPS (Diluted)	-0.49	-0.66	-0.49	-2.19	-1.28	-2.97
EPS Growth	-12%	36%	-78%	71%	-56.99%	28.99%
Free Cash Flow	-17	-15	-27	-75	-103	-91
Free Cash Flow Per Share	-0.37	-0.33	-0.61	-1.71	-2.38	-2.26
Gross Margin	81.17%	82.75%	86.9%	87.69%	94.11%	--
Operating Margin	-30.58%	-33.33%	-25%	-144.61%	-338.23%	-595%
Profit Margin	-25.88%	-33.33%	-25%	-146.15%	-161.76%	-595%
Free Cash Flow Margin	-20%	-17.24%	-32.14%	-115.38%	-302.94%	-455%
EBITDA	-26	-29	-21	-94	-115	-119
EBITDA Margin	-30.58%	-33.33%	-25%	-144.61%	-338.23%	-595%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-26	-29	-21	-94	-115	-119
EBIT Margin	-30.58%	-33.33%	-25%	-144.61%	-338.23%	-595%
Effective Tax Rate	0%	0%	0%	--	--	--